A secondary analysis of the 450-patient, randomized ATLAS trial suggests Boston Scientific's Emblem MRI subcutaneous implantable cardioverter defibrillator (S-ICD) can help prevent tricuspid valve regurgitation in arrhythmia patients.
Darryl Leong from McMaster University in Hamilton, Ontario presented the research at the Heart Rhythm 2023 conference in New Orleans.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?